LDN Social Media
Get connected with us on social networks
Phase 2 Trial to Evaluate Safety and Efficacy of CYTO-205 in Mild COVID-19
ClinicalTrials.gov
13 January 2021
https://www.clinicaltrials.gov/ct2/show/NCT04708327?term=Cytocom&draw=2&rank=1
The aim of the study is to assess the safety and clinical efficacy of low-dose naltrexone (CYTO-205; Cytocom, Inc) in reducing the proportion of higher risk patients who progress from mild COVID-19 to a more severe disease category.